SGLT2 inhibitors should be first-line treatment in HFrEF - discussion

26 August 2023 (09:00 - 09:15)
Organised by: Logo
Congress Presentation Part of: Great Debate: controversies in the contemporary management of HFrEF Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

ESC 365 is supported by

ESC 365 is supported by